Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Benefit-risk assessment of bevacizumab in the treatment of breast cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Benefit-risk assessment of bevacizumab in the treatment of breast cancer.
Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf. 2012 Jan 01; 35(1):15-25.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Breast Neoplasms
Female
Humans
Randomized Controlled Trials as Topic
Risk Assessment
Time Factors
Vascular Endothelial Growth Factor A